BOSQF:OTC-Better Plant Sciences Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 0.06

Change

0.00 (0.00)%

Market Cap

USD 9.34M

Volume

0.63M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Better Plant Sciences Inc., through its subsidiaries, develops, markets, and sells of plant-based products for health and wellness. The company offers cosmetic and therapeutic products made of cannabis sativa hemp root oil and essential oils. It also develop and acquire intellectual property for plant-based products. The company offers plant-based skin care products under Urban Juve brand name; cannabis wellness products under Wright & Well and Jack n Jane brands; botanicals, fruit extracts, and spices under the UJ Beverages brand. The company was formerly known as The Yield Growth Corp. and changed its name to Better Plant Sciences Inc. in August 2020. Better Plant Sciences Inc. was incorporated in 2014 and is headquartered in Vancouver, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.04 (+0.14%)

USD63.83B 37.72 17.60
MKGAF MERCK Kommanditgesellschaft au..

+4.50 (+3.15%)

USD61.98B 37.74 17.60
TKPHF Takeda Pharmaceutical Company ..

+1.22 (+3.34%)

USD57.55B 51.33 0.13
ESALY Eisai Co., Ltd

+1.75 (+1.94%)

USD25.68B 21.76 0.14
ESALF Eisai Co., Ltd

N/A

USD25.66B 21.85 0.14
SFOSF Shanghai Fosun Pharmaceutical ..

-0.02 (-0.36%)

USD17.25B 20.84 2.64
SGIOF Shionogi & Co., Ltd

-0.87 (-1.58%)

USD16.38B 15.12 0.08
SGIOY Shionogi & Co., Ltd

+0.29 (+2.12%)

USD16.32B 15.22 0.08
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

N/A

USD9.49B 904.00 16.09

ETFs Containing BOSQF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -63.91% 22% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.91% 22% F 9% F
Trailing 12 Months  
Capital Gain -72.04% 29% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.04% 29% F 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.29% N/A N/A 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.29% N/A N/A 6% F
Risk Return Profile  
Volatility (Standard Deviation) 34.14% N/A N/A 52% F
Risk Adjusted Return -79.92% N/A N/A 7% F
Market Capitalization 9.34M 52% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.73 26% F 28% F
Price / Cash Flow Ratio -0.78 44% F 66% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -364.64% 13% F 5% F
Return on Invested Capital -1,068.95% 3% F 1% F
Return on Assets -122.30% 11% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.80 29% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector